JMP Securities Initiates Coverage On Zevra Therapeutics with Market Outperform Rating, Announces Price Target of $17
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has initiated coverage on Zevra Therapeutics with a Market Outperform rating and set a price target of $17.
September 24, 2024 | 1:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has initiated coverage on Zevra Therapeutics with a Market Outperform rating and a price target of $17, indicating a positive outlook.
The initiation of coverage with a Market Outperform rating and a price target of $17 by JMP Securities suggests a positive sentiment towards Zevra Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100